Gene therapy for Duchenne muscular dystrophy (DMD) will require sustained expression of therapeutic dystrophins in striated muscles. Lentiviral vectors have a relatively large transgene carrying capacity and can integrate into nondividing cells. We therefore explored the use of lentiviral vectors for transferring genes into mouse skeletal muscle cells. These vectors successfully transferred a minidystrophin expression cassette into mdx muscles, and minidystrophin expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months. However, only low to moderate levels of skeletal muscle transduction could be obtained by intramuscular injection of the highest currently available lentiviral doses. Using cultured cells, the lentiviral vectors effectively transduced proliferating and terminally differentiated muscle cells, indicating that cell cycling is not essential for transduction of myogenic cells. We further showed that lentiviral vectors efficiently transduced both primary myoblasts and multipotent adult progenitor cells (MAPCs) in vitro, and the cells persistently expressed transgenes without any obvious toxicity. When mdx primary myoblasts were genetically modified with minidystrophin vectors and transplanted into mdx skeletal muscles, significant numbers of dystrophin-expressing myofibers formed. Finally, we showed that a short, highly active CK6 regulatory cassette directed muscle-specific activity in the context of the lentiviral vectors. The ability of lentiviral vectors to transduce myogenic progenitors using a minidystrophin cassette regulated by a muscle-specific promoter suggests that this system could be useful for ex vivo gene therapy of muscular dystrophy.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder characterized primarily by progressive weakness, loss of skeletal muscle, and cardiomyopathy. 1 As DMD is recessively inherited, it has been postulated that gene replacement therapy could lead to a treatment for this disorder. 2 We and others have demonstrated that replacement of dystrophin in transgenic mdx mice restores normal expression of the dystrophinglycoprotein complex and prevents skeletal muscle pathology from developing. 3, 4 Also, delivery of full-length and some truncated dystrophins to adult skeletal muscles using viral vectors has been shown to reverse partially the dystrophic pathology in mdx limb muscles. 2, [4] [5] [6] Successful gene and cell therapy for DMD will require sustained dystrophin expression in skeletal and cardiac muscles. 2 To date, most efforts toward dystrophin delivery have used adenoviral (Ad) or recombinant adeno-associated viral (rAAV) vectors, neither of which has been shown to integrate into myonuclear genomic DNA. 7, 8 Consequently, while these vectors can efficiently transduce striated muscle, their ability to support transgene expression for more than a few years is unclear. 4, [9] [10] [11] Lentiviral vectors derived from the human immunodeficiency virus-1 (HIV-1) can integrate into the host genome and achieve long-term transgene expression in a wide variety of dividing and nondividing cells including skeletal muscle. [12] [13] [14] [15] The potential use of this vector system for stable gene transfer to muscle is therefore of great interest, as it could theoretically be used for gene transfer to postmitotic myofibers or to a variety of stem cells with myogenic potential.
Skeletal muscle of adult vertebrates is mainly composed of terminally differentiated, postmitotic multinucleated myofibers that are associated with a small population of quiescent satellite cells. In response to muscle damage, the satellite cells become activated and proliferate to generate numerous myoblasts that fuse with damaged myofibers, or with themselves, to repair damaged fibers. 16 Recently, new populations of stem cells with myogenic potential have been identified. [17] [18] [19] Vectors with an ability to target these myogenic progenitors could be useful for ex vivo gene therapy of muscle diseases by enabling the generation of genetically modified stem cells for muscle regeneration.
Several studies have examined the ability of lentiviral vectors to transduce adult skeletal muscle. Kafri et al 12 first reported lentiviral transduction of rat tibialis anterior (TA) muscle in which green fluorescence protein (GFP) expression persisted for at least 4 weeks without an obvious immune response. Seppen et al 13 showed sustained secretion of erythropoietin (EPO) from rat skeletal muscles following intramuscular injection of a lentiviral vector. Both groups used lentiviral vectors pseudotyped with the vesicular stomatitis virus envelope glycoprotein (VSV-G). However, no direct evidence indicates whether these vectors can transduce postmitotic myofibers, or whether they preferentially transduce satellite cells or myoblasts that have been activated following the trauma of vector injection. A more recent study found that VSV-G-pseudotyped lentiviral vectors were relatively inefficient at transducing embryonic mouse skeletal muscle, although lentiviral vectors pseudotyped with envelope glycoproteins derived from either the Mokola or Ebola viruses mediated higher transduction efficiencies. 14 A particular advantage of lentiviral vectors is their relatively large cloning capacity of B9 kb, sufficient to carry an expression cassette for a fully functional minidystrophin. Consequently, we explored the potential of this vector system to transfer both reporter and minidystrophin genes to mouse skeletal muscle and myogenic precursor cells. We found that VSV-G-pseudotyped lentiviral vectors transduced adult mouse skeletal muscle with a relatively low efficiency. Nonetheless, 
Results

Lentiviral vectors mediate transgene expression in skeletal muscle
We first asked whether the lentiviral vectors could efficiently mediate transgene expression in mouse skeletal muscles. The L-MSCV-eGFP vectors were injected intramuscularly into TA muscles of 2-month-old C57Bl/10 mice. By 2 weeks postinjection, GFP expression was observed in the injected muscles (data not shown). GFP expression was still obvious 1 month postinjection in a relatively limited area of the TA muscles ( Figure 1a) . We further confirmed GFP expression by Western analysis using polyclonal antibodies against GFP (data not shown). Likewise, a 5-month-old mdx TA muscle injected with the L-CMV (cytomegalovirus)-ntsLacZ vectors showed lacZ expression at 2 weeks postinjection (Figure 1b) , although the number of lacZ-expressing myofibers was limited.
Development of a minidystrophin-expressing lentiviral vector
The relatively large transgene carrying capacity of lentiviral vectors make it possible to deliver a 6.8-kb minidystrophin cDNA. The minidystrophin encoded by this cDNA (DH2-R19) contains eight spectrin-like repeats and has been shown to be fully functional when analyzed in muscles of transgenic mdx mice. 4 We transduced proliferating mdx myoblasts, a permanent myogenic cell line derived from mdx mice (Hauschka, unpublished data), at an MOI of 100 using L-CMV-DH2-R19 vectors. The transduced myoblasts were expanded in growth medium for several days, and then induced to form myotubes. We detected minidystrophin expression by immunostaining in myotubes fused from L-CMV-DH2-R19-transduced mdx myoblasts (Figure 2a ). The minidystrophin expression was further confirmed by Western blot analysis of C2C12 cells transduced with L-CMV-DH2-R19 viruses (data not shown).
We then asked whether the minidystrophin lentiviral vectors could transduce mdx skeletal muscles in vivo. We intramuscularly injected L-CMV-DH2-R19 vectors into quadriceps of 6-day-old mdx mice. After 1 month, the vector-injected quadriceps expressed minidystrophin in a relatively limited area, and the expression persisted for 6 months, the longest time point analyzed (Figure 2b) . Importantly, the minidystrophin-expressing myofibers excluded Evans blue dye, indicating a functional preservation of sarcolemmal integrity in these fibers (Figure 2b ). These results indicated that integrating lentiviral vectors can transduce dystrophic muscles with a minidystrophin gene, which is both larger and more functional than microdystrophin genes being tested in rAAV vectors, 4 and that expression persists for at least 6 months.
Lentiviral vectors mediate gene transduction of proliferating and differentiated mdx myogenic cells
We examined the transduction efficiency of lentiviral vectors on a permanent myogenic cell line derived from mdx mice (Hauschka, unpublished data). A lentiviral vector, L-MSCV-eGFP, was used to transduce proliferating mdx myoblasts at an MOI of 100. After 2 days, essentially all the myoblasts expressed GFP ( Figures 3a  and b) ; at an MOI of 10, 460% of the myoblasts expressed GFP (data not shown). These data demonstrated that the lentiviral vector efficiently transduced proliferating mdx myoblasts in vitro.
Direct gene transfer into skeletal muscles requires vectors capable of transducing nondividing muscle cells, since adult muscle is mainly composed of terminally differentiated, postmitotic myofibers. We therefore asked whether the lentiviral vector could transduce nondividing myocytes or myotubes in vitro. Cultures of proliferating myoblasts were switched to differentiation media for at least 3 days. At this point, 495% of the cells expressed myosin heavy chain (Figure 3g ), indicating that they had committed to terminal differentiation and become permanently nondividing muscle cells. The Each quadriceps muscle of 6-day-old mdx mice was injected with 10 ml L-CMV-DH2-R19 (5.9 Â 10 6 IU). Cryosections were prepared 1 month or 6 months after injection and immunostained for dystrophin. The bottom row shows Evans blue dye fluorescence in the quadriceps of a mouse 6 months postinjection. Most fibers expressing minidystrophin excluded the dye. Scale bar, 100 mm.
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L-MSCV-eGFP vectors were used to transduce this muscle cell population at an MOI of 100. All cells, including differentiated myocytes and myotubes, expressed GFP (Figures 3h and i ). In addition, we observed efficient transduction of cultures containing predominantly large myotubes after incubating them with L-CMV-ntsLacZ or L-CK6-ntsLacZ vectors (data not shown). These data indicated that lentiviral vectors could efficiently transduce nondividing muscle cells, including myocytes and myotubes, in vitro.
Genetically modified mdx myoblasts retain myogenic potential
We next asked whether the vector-transduced myoblasts retained normal developmental properties. The L-MSCVeGFP-transduced mdx myoblasts were maintained in growth medium for 3 days, and then switched to differentiation medium (the first differentiation day was designated as D1). GFP expression was detected in almost all myoblasts 48 h postinfection. These GFPexpressing cells proliferated in growth medium and differentiated into myocytes in differentiation medium. As shown in Figures 3c and d , many GFP-expressing myotubes were detected by D8. The GFP-expressing myotubes continued to form and grow throughout the period examined. At Day 11, the cultures were composed predominantly of GFP-expressing myotubes, some of which contracted (Figures 3e and f) . As shown in Figure  3l , the GFP-expressing myotubes synthesized myosin and displayed normal myofilament assembly. In addition, myocytes transduced with lentiviral vectors also Proliferating mdx myoblasts (a-f) and differentiating mdx myocytes and myotubes (g-k) were transduced with L-MSCV-eGFP at an MOI of 100. At 3 days after transduction, the myoblast cultures were induced to differentiate. Cultures transduced while proliferating were photographed 2, 8, and 11 days after inducing terminal differentiation; differentiating cultures were transduced 3 days after a switch to differentiation media and were photographed 8 and 11 days after induction of terminal differentiation (5 and 8 days after lentiviral transduction). (g) Myosin heavy-chain staining was performed on day 3, the same day that the myocyte/myotube cultures were transduced. Greater than 95% of the cells at this time stained positive for myosin heavy chain, indicating that they had irreversibly withdrawn from the cell cycle and committed to terminal differentiation. 27 ,28 a, c, e, h, and j: bright field; b, d, f, i, and k: GFP fluorescence. (l) Mdx myoblasts were transduced with L-MSCVeGFP virus, and were induced to differentiate. The cultures were stained with DAPI and a myosin heavy-chain monoclonal antibody (F59). Photographs were taken at Â 400 (top) and Â 1000 (bottom) magnification. Figure 4a ). Figure 4b shows a representative myoblast colony expressing GFP. Once switched to differentiation medium, this colony formed GFP-expressing myotubes that expressed myosin heavy chain. Mouse MAPCs from bone marrow and skeletal muscle possess myogenic potential. 19 We examined whether lentiviral vectors could effectively transduce mouse MAPCs. MAPCs isolated from wild-type mouse skeletal muscle were transduced with L-MSCV-eGFP vectors at an MOI of 10. Essentially all MAPCs expressed GFP 2 days post-transduction. We cultured these transduced cells in MAPC medium for at least 6 months (440 population doublings), and did not observe any apparent loss of GFP expression (Figure 4c) .
We then transduced freshly isolated mdx myoblasts with L-CMV-H2-R19 vectors at an MOI of 10. These cells were cultured in myoblast growth medium for 48 h; and about one million cells were transplanted into each mdx TA muscle. After 2 weeks, we found numerous newly regenerated myofibers in the transplanted muscles (Figure 4d) . However, these dystrophin-positive myofibers were surrounded with numerous infiltrating mononuclear cells (Figure 4e ), suggesting that an immune Stable gene transfer into myogenic cells S Li et al response had developed. This type of immune response was not eliminated by using lentiviral vectors bearing a muscle-specific promoter (data not shown), consistent with observations by others using either adenoviral (Ad) or herpes viral vectors for autologous transplantation of mdx mice. [20] [21] [22] Similarly, mdx MAPCs genetically modified with microdystrophin regulated by a musclespecific promoter, when injected intramuscularly, also generated dystrophin-expressing myofibers in mdx skeletal muscles (Reyes et al, submitted) .
CK6 regulatory cassette maintains muscle-specific activity in lentiviral vector-transduced cells
Muscle-specific transgene expression can prevent immune responses elicited by the expression of some transgenes in antigen-presenting cells (APCs). 23, 24 Effective gene therapy for muscle disorders may therefore require the use of vectors that express transgenes exclusively in muscle fibers. A 571-bp CK6 regulatory cassette derived from the mouse muscle creatine kinase (MCK) gene has previously been shown to maintain muscle-specific activity when tested in Ad and rAAV vectors, which exist as episomes in host cells. 6, 23, 25 However, since lentiviral vectors integrate into the host genome, we asked whether sequences within the vector genome might interfere with the muscle and differentiation specific activity of the CK6 promoter.
First, we transduced MM14 myoblasts 26, 27 derived from wild-type mice with L-CK6-eGFP vectors and isolated a clone. When cultured in proliferation medium, these myoblasts did not show GFP expression (Figures  5a and b) . Following a switch to differentiation medium, the myocytes and myotubes began to express GFP. The GFP-expressing cells also expressed myosin heavy chain, a marker for terminally differentiated muscle cells (Figures 5c-f) . These data are consistent with the previous observation showing that the MCK promoter is only active in differentiated muscle cells. 28, 29 Second, freshly isolated single myofibers were immediately incubated for 4 h with L-MSCV-eGFP or L-CK6-eGFP vectors, and then grown in MethoCult media for various times to allow proliferation of activated satellite cells and subsequent myotube formation. We monitored GFP expression in various types of cells in the cultures at different time points. At 3 days after culture, we observed that, in the L-MSCV-eGFP virus-transduced culture, all types of cells including fibroblasts, myoblasts, myocytes, myotubes, macrophages, and adipocytes, expressed GFP. In contrast, cultures incubated with L-CK6-eGFP displayed green fluorescence exclusively in myocytes and myotubes from day 5 to day 22. Figures 5g-j show representative photographs in which GFP expression was observed in L-MSCV-eGFP-transduced muscle cells and fibroblasts, while GFP was exclusively expressed in myocytes or myotubes in the culture transduced with L-CK6-eGFP. These data indicated that the CK6 regulatory cassette maintained muscle-specific transcriptional activity in lentivirally transduced cells.
Discussion
Lentiviral vectors have attracted considerable attention for potential use in gene and cell therapies due to their relatively large cloning capacity coupled with an ability to transduce nondividing cells. 30 While the relative ability of lentiviral vectors to transduce postmitotic cells versus dividing cells has been controversial, several modifications to the vector backbone may have resulted in an increased ability to transduce nondividing cells. 13, 31, 32 One such modified, third-generation VSV-Gpseudotyped lentiviral vector has been used to transfer an EPO cDNA into rat skeletal muscles. 13 MacKenzie et al 14 reported that VSV-G-pseudotyped lentiviral vectors 14 we explored the potential of VSV-G vectors to transduce a variety of mouse skeletal muscle cells both in vitro and in vivo.
Using mdx cell lines and primary myoblast cultures, we demonstrated that essentially 100% of the cells could be stably transduced at MOIs in the range 50-100. This transduction was not accompanied by noticeable toxicity, as the cells did not display a loss of viability or a reduction in proliferation potential (Figures 3 and 4b) . Transduced myoblasts could differentiate and form myotubes that displayed a normal cytoarchitecture, were frequently observed to contract, and expressed muscle-specific genes such as myosin heavy chain (Figures 3 and 4b) .
Transduction was not limited to proliferating myoblasts, as we also efficiently transduced nondividing muscle cells in vitro (Figures 3g-k) . Transduction of these terminally differentiated myocytes indicated that cell cycling is not required for lentiviral transduction of muscle cells, consistent with previous observations on neurons, glial cells, primary hepatocytes, and hematopoietic stem cells. 31, 33, 34 A unique feature of skeletal muscle biology is its enormous regenerative potential. In addition to satellite cells that were previously thought to be the only cell source for muscle regeneration, other cell types, such as SP cells and MAPCs in various tissues, possibly originating from the vascular endothelium, may also contribute to muscle repair. 17, 19, 35, 36 We have previously shown that lentiviral vectors mediate microdystrophin gene transfer to mdx muscle SP cells, and that transduced SP cells can deliver dystrophin genes to regenerating mdx muscle fibers following tail vein transplantation. 36 Kobinger et al 15 showed that lentiviral vectors can transduce satellite cells in vivo. In the present study, we demonstrated that lentiviral vectors could efficiently transduce muscle MAPCs and that transgene expression in MAPCs persisted for at least 6 months during exponential growth in vitro (Figure 4c ). Taken together, these studies suggest that VSV-G-pseudotyped lentiviral vectors can target a variety of myogenic precursor and progenitor cells. Since these vectors stably integrate into host cell chromosomes, their use in gene and cell therapy applications potentially provides a method for long-term therapeutic gene expression in muscle tissue including damaged or diseased muscles actively undergoing regeneration.
In contrast to the high transduction efficiency of muscle cells in vitro, the lentiviral vectors at concentration of 1-10 Â 10 8 IU/ml did not provide high levels of gene transfer when injected directly into mature mouse muscle (Figures 1 and 2 ). Several factors may account for these differences including differences in viral receptor expression in vitro versus in vivo, physical barriers to viral spread within muscle, immune responses, and the titer of the vector preparations. For Ad vectors, the major viral attachment receptors, coxsackie adenovirus receptor and the integrins a v b3 and a v b5, are downregulated during myoblast differentiation and myofiber maturation. 37, 38 Thus, Ad vectors were found to primarily target satellite cells, myoblasts and immature myofibers, and the highest transduction of skeletal muscle mediated by Ad is achieved in neonatal or regenerating muscle tissue. 5, [37] [38] [39] Effective transduction by VSV-G-pseudotyped lentiviral vectors also requires appropriate expression of several proteins such as heparan sulfate proteoglycans and glycosaminoglycans (GAGs) on target cell surfaces. 40 However, the seeming inefficiency of lentiviral transduction of muscle in vivo relative to cultured cell lines may not be due primarily to differences in receptor levels, since we efficiently transduced freshly isolated single myofiber fragments and primary myoblasts from mice (Figures 4a, b, and 5b) . Kobinger et al reported that improved transduction of young adult skeletal muscle was achieved using vectors pseudotyped with alternate envelope glycoproteins. Vectors pseudotyped with the Ebola virus envelope were able to transduce mdx mouse myofibers and satellite cells in a highly mosaic pattern, which was nonetheless capable of inducing a measurable increase in muscle contractile properties. 15 Another important factor may be the relative accessibility of the myofiber sarcolemma to vector binding, as the extracellular matrix surrounding myofibers may form a physical barrier preventing virus diffusion and attachment. It has been suggested that the extracellular matrix interferes with adenovirus-mediated transduction of mature skeletal muscles. 41 The relatively large size of lentiviral particles (90-130 nm) may render them less able to penetrate this barrier than either Ad particles (70-100 nm) or AAV particles (B25 nm). 42 An immune response against foreign proteins may also lead to a relatively low lentiviral transduction efficiency of adult skeletal muscle in vivo. We found that in the LacZ-vector-injected TA muscles, b-galactosidase activity decreased dramatically by 4 weeks post-injection (data not shown), suggesting a possible immune response against transduced myofibers. Vector-mediated immune responses have previously been observed in a variety of tissues, including muscle, following injection with either Ad, rAAV, or lentiviral vectors. 23, 24, 43 These responses can be directed against vector proteins, foreign transgene expression, or impurities in the viral preparation. Most of these immune responses could be blunted by the use of modified vector backbones (eg by using 'gutted' vectors), muscle-specific promoters (in either Ad or rAAV vectors), or by using ultrapurified vector preparations (eg HPLC purification of lentiviral vectors). 5, 6, 23, 24, 43 However, we observed that muscles transduced with the L-CK6-ntsLacZ still showed decreased b-galactosidase activity with increasing time (data not shown), while dystrophin expression from the L-CMV-DH2-R19 vector appeared stable (Figure 2b) .
The major barrier to lentiviral transduction of mature muscle may simply be the relative concentration of vector particles available from present purification protocols. A typical titer of lentiviral vectors obtained from our studies and those of others is in the range of 10 10 IU/ml. 44 In contrast, Ad and AAV vectors can be routinely obtained at concentrations of B10 13 vg/ml. 45, 46 However, the transduction efficiency of muscle fibers by lentiviral vectors (Figures 1 and 2b) , on a particle to particle basis, is similar to what can be obtained from an equivalent dose of rAAV6. 47 In summary, we have shown that VSV-G-pseudotyped lentiviral vectors can transduce various types of mouse Stable gene transfer into myogenic cells S Li et al muscle cells both in vitro and in vivo. These vectors can carry a highly functional minidystrophin gene that is too large to be carried by rAAV, and they also have the capacity to carry larger regulating cassettes. The stable transduction of muscle cells by an integrating vector suggests that lentiviral vectors could be of use for either direct transduction of muscle cells in vivo or for ex vivo gene therapy strategies following transduction of myogenic stem cells. Importantly, residual lentiviral genomic sequences do not appear to compromise the muscle and differentiation specific activity of the CK6 regulatory gene cassette. However, additional studies focused on vector purification, and methods to increase both the yield and titer of vector stocks will be needed to determine the long-term potential of this vector system for gene and cell therapy of muscle diseases.
Materials and methods
Mouse strains C57BL/10ScSn-Dmd mdx /J ('mdx') and C57Bl/10ScSn ('C57BL/10') mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA) or from our breeding colonies at the University of Washington.
Cell lines
293T cells were grown as described previously. 23 The mdx and MM14 myoblast cell lines were cultured on 0.67% gelatin-coated plates in medium containing F10C plus 15% horse serum and 5 ng/ml recombinant human basic FGF-2 (R&D systems). Differentiation was induced by rinsing the cultures and switching them to medium containing F10C with 1.5% horse serum and 6 mg/ml insulin for 48 h, followed by refeeding cultures with F10C with 15% horse serum and insulin.
Construction of lentiviral transfer vectors and viral preparation
Transfer vectors were constructed by inserting the corresponding coding sequences into the polylinker of the pRRL-cPPT-CMV-X-PRE-SIN vector. 48 For some transfer vectors, the human CMV promoter was replaced with the murine stem cell virus promoter (MSCV) 49 or the CK6 promoter. 25 VSV-G-pseudotyped lentiviral vectors were produced by cotransfecting 293T cells, and purified by ultracentrifugation as described. 48 The titer of viruses containing reporter genes was measured by transducing Hela cells with serial dilutions of vector preparations. The titer of other vector stocks was estimated by measuring viral p24 gag antigen using the HIV-1 p24 Antigen Assay kit (Beckman Coulter Inc.) and comparing to the titer of vectors with reporter genes as described. 48 Single myofiber isolation and culture TA muscles were digested with 0.2% Collagenase II (Worthington Biochemical Corporation) for 40 min. Single myofibers were obtained by pipetting up and down using a Pasture pipette and then cultured in MethoCult GF M3534 medium (StemCell Technologies).
Primary myoblast culture
Limb muscles from 1-month-old C57Bl/10 mice were excised, minced, and digested in 1 Â PBS with final concentrations of 1 mM CaCl 2 , 0.2% Collagenase II, and 1.2 U/ml Dispase at 371C for 45 min, and then filtered through 70-and 40-mm nylon filters (BD Falcon). Mononuclear cells were cultured as described above for the mdx myoblast cell line.
Isolation of muscle MAPCs
Mononuclear cells from limb muscles of 1-month-old C57Bl/10 mice were prepared as described above and then cultured in mouse MAPC medium as described previously. 19 The multipotent differentiation capacity of isolated MAPCs was examined by in vitro differentiation assay 19 before and after viral vector transduction.
In vitro viral transduction
Various amounts of vectors were mixed in an appropriate growth medium in the presence of 8 mg/ml polybrene (Sigma) for 5 min, and then added to the cells. Growth medium was changed at 16 h posttransduction.
Intramuscular injection of TA muscles
Injection of vectors or transduced primary myoblasts into muscles was performed as described previously. 25 Briefly, mice were anesthetized with 20 mg/ml Avertin (10 ml/g), and 10 ml (for 6-day-old mice) or 25 ml (for all other ages) of viral preparations with titers from 2 to 13 Â 10 8 IU/ml or 40 ml of one million cells was injected into TA muscles; control mouse muscles were injected with 0.9% sodium chloride.
b-galactosidase staining and Evans blue dye assay TA muscles were stained for b-galactosidase activity as described previously. 25 Evans blue assays were performed as described previously. 4 In brief, mice were injected intraperitoneally with 300 ml PBS with 10 mg/ml Evans blue dye 16 h before excising and freezing the quadriceps in OCT embedding medium. Images were collected as described below.
Immunostaining cultured muscle cells and frozen muscle sections
Cultured muscle cells were fixed in 2% paraformaldehyde for 10 min and permeated with 1% Triton X-100 for 10 min before immunostaining. These cells were then incubated with DYS2 monoclonal antibody (Novocastra Laboratories Ltd), or F59 myosin heavy-chain monoclonal antibody 50 for 1 h, followed by incubation with either Alexa 594-or Alexa 488-conjugated secondary antibodies (1:1200) (Molecular Probes) for 1 h. Muscle sections were immunostained as described previously. 4 Images were collected on a Nikon E1000 microscope under identical conditions using a Spot II CCD camera.
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